Navigation Links
Early results from clinical trials of 2009 H1N1 influenza vaccines in healthy adults
Date:9/11/2009

We are encouraged by reports that are now emerging from various clinical trials of 2009 H1N1 influenza vaccines, conducted by various vaccine manufacturers. We expect additional companies to announce their preliminary trial results shortly. The early data from these trials indicate that 2009 H1N1 influenza vaccines are well tolerated and induce a strong immune response in most healthy adults when administered in a single unadjuvanted 15-microgram dose. We congratulate the companies on these trials, which are an important part of the ongoing worldwide effort to develop vaccines to protect the public from 2009 H1N1 influenza.

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, also is conducting clinical trials of 2009 H1N1 influenza vaccines, produced by Sanofi Pasteur and CSL Limited. The NIAID trials are testing two different dosages (15 micrograms versus 30 micrograms) and evaluating the immune response to one and two doses of these vaccines. More than 2,800 people are participating in ongoing NIAID trials of these vaccines.

We are pleased to note that preliminary analyses of early data from the NIAID trials align with the recently announced findings and those to be announced imminently by other companies in that both vaccines studied induced what is likely to be a protective immune response in most adults following a single dose in the same amount (15 micrograms) used in seasonal flu vaccines. Specifically, in blood samples obtained 8 to 10 days after vaccination

  • Among healthy adults who received a single 15-microgram dose of the Sanofi Pasteur vaccine, a robust immune response was measured in 96 percent of adults aged 18 to 64 and in 56 percent of adults aged 65 and older.

  • Similarly, among healthy adults who received a single 15-microgram dose of the CSL Limited vaccine, a robust immune response was measured in 80 percent of adults aged 18 to 64 and in 60 percent of adults aged 65 and older.

Additional data from the NIAID trials are forthcoming. However, on the basis of these strong early data, our results are consonant with other reports that a single 15-microgram dose of unadjuvanted 2009 H1N1 influenza vaccine is well tolerated and induces a robust immune response in healthy adults between the ages of 18 and 64. For adults aged 65 and older, the immune response to 2009 H1N1 influenza vaccine is somewhat less robust, as is the case with seasonal influenza vaccines.

We note that the slight discrepancies seen in our trials between the Sanofi Pasteur and CSL Limited vaccines may be due to technical differences in the preliminary measurement of the amounts of antigen in the doses used in the clinical trial lots and the relatively limited numbers of samples studied to date, as well as the fact that our data are drawn from a very early time point after immunization.


'/>"/>

Contact: NIAID Office of Communications
niaidnews@niaid.nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
Source:Eurekalert

Related medicine news :

1. Cardinal Health Announces Early Tender Results of Debt Tender Offer
2. Americans Urged To Get Seasonal Influenza Vaccine Early
3. CI Faculty Member Awarded Nearly $1 Million NSF Grant
4. Give an Hour(TM)s Volunteer Mental Health Professionals Provide Nearly $1.7 Million in Services to Iraq and Afghanistan Veterans, Families, and Communities
5. FDA Clears Hologics MammoSite(R) ML Radiation Therapy System for the Treatment of Early-Stage Breast Cancer
6. Excuse Me, Your Life Is Waiting!: A Bridge from Addiction to Early Recovery
7. Narrow-band imaging increases specificity of early lung cancer detection
8. New Therapy Spares Organ in Early Esophageal Cancer
9. Blood Test May Spot Pancreatic Cancer Early
10. Regence Foundation Awards Nearly $250,000 in Grants to Northwest Nonprofits
11. EPIX Pharmaceuticals, Inc. Announces the P2Y2 Gastrointestinal Early Development Candidate Program Will Be Part of the Intellectual Property Offered For Sale at the September 30, 2009 Auction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/25/2017)... ... September 25, 2017 , ... ... Community”: a gripping look at the religious stand in the sensitive matter ... love and compassion. “The Ministry of Reconciliation: A Compassionate and Realistic Approach to ...
(Date:9/25/2017)... ... September 25, 2017 , ... Netmail, Inc . and ... Netmail’s Hadron Data Auditing and eDiscovery services to healthcare organizations ... their Hadron solution in a HIPAA/HITRUST Azure Cloud at the Microsoft Ignite #MSIgnite conference ...
(Date:9/25/2017)... , ... September 25, 2017 , ... ... Preconference Workshop, **Presented by FDAnews**, Nov. 1-3, 2017 – Bethesda, MD, http://www.fdanews.com/fdainspectionssummit ... with flying colors. And then, on the tenth inspection it failed. , What ...
(Date:9/24/2017)... ... , ... Bhowanie Benimadhu’s new book “ Our Creative World: Our Created Life ... answers in both Eastern and Western religious traditions and spirituality such as Hinduism ... of humankind for the past thousands of years and still are,” Benimadhu says. “By ...
(Date:9/24/2017)... Michigan (PRWEB) , ... September 23, 2017 , ... Throughout ... do no harm. , Every day, physicians, nurses and other providers work to ... treatments and innovative industry processes. , But U.S. Senators today are threatening to ...
Breaking Medicine News(10 mins):
(Date:9/18/2017)... PROVIDENCE, R.I. , Sept. 18, 2017 ... in the fields of bioinformatics and immune ... to develop a protective avian influenza A (H7N9) vaccine. ... is distantly related to seasonal influenza and ... approaches, which rely on prior exposure to be ...
(Date:9/12/2017)... , Sept. 12, 2017  ValGenesis Inc., the ... (VLMS), is pleased to announce the appointment of ... of its Board of Directors and Chairman of ... enables life science companies to manage their entire ... of paper in this process. Furthermore, ValGenesis VLMS ...
(Date:9/7/2017)... 2017  Eli Lilly and Company (NYSE: ... operations to more efficiently focus resources on developing ... Global workforce reductions, including those from a U.S. ... approximately 3,500 positions. With the ... of approximately $500 million that will begin to ...
Breaking Medicine Technology: